SCHEMBL25755512

SCHEMBL25755512

COc1ccc(NC(=O)c2ncc[nH]2)cc1S(=O)(=O)Nc1ccc(Br)cc1

nearest known ligand 0.62

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 5/20 0.62
LMNA P02545 5/20 0.62
MEN1 O00255 4/20 0.62
SMN1; SMN2 Q16637 4/20 0.62
ALDH1A1 P00352 3/20 0.62
ALOX12 P18054 2/20 0.62
GAA P10253 2/20 0.62
CRHBP P24387 1/20 0.62
CRHR2 Q13324 1/20 0.62
MAPT P10636 7/20 0.58
KDM4E B2RXH2 1/20 0.54
NPC1 O15118 1/20 0.54
HTT P42858 1/20 0.54
ITGB3 P05106 1/20 0.52
ITGAV P06756 1/20 0.52
HPGD P15428 1/20 0.51
ALPL P05186 4/20 0.47
HDAC1 Q13547 1/20 0.47
HDAC8 Q9BY41 1/20 0.47
HDAC6 Q9UBN7 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25755590 0.82 KMT2A (0.67) KMT2ALMNAMEN1SMN1; SMN2ALDH1A1
SCHEMBL30199535 0.80 KMT2A (0.59) KMT2ALMNAMEN1SMN1; SMN2ALDH1A1
SCHEMBL23833718 0.80 KMT2A (0.59) KMT2ALMNAMEN1SMN1; SMN2ALDH1A1
SCHEMBL25755498 0.80 KMT2A (0.62) KMT2ALMNAMEN1SMN1; SMN2ALDH1A1
SCHEMBL23846521 0.80 LMNA (0.62) KMT2ALMNAMEN1SMN1; SMN2ALDH1A1
SCHEMBL23846438 0.80 KMT2A (0.62) KMT2ALMNAMEN1SMN1; SMN2ALDH1A1
SCHEMBL25755514 0.80 KMT2A (0.64) KMT2ALMNAMEN1SMN1; SMN2ALDH1A1
SCHEMBL25755504 0.79 MAPT (0.82) KMT2ALMNAMEN1SMN1; SMN2ALDH1A1
SCHEMBL25755588 0.78 MAPT (0.67) KMT2ALMNAMEN1SMN1; SMN2ALDH1A1
SCHEMBL25755495 0.78 MAPT (0.67) KMT2ALMNAMEN1SMN1; SMN2ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230174523-A1 BENZENESULFONAMIDE DERIVATIVES AS TRAP1 MODULATORS AND USES THEREOF AMATHUS THERAPEUTICS, INC. (US) 2023-06-08 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230174523-A1 BENZENESULFONAMIDE DERIVATIVES AS TRAP1 MODULATORS AND USES THEREOF TRAP1, PINK1, TP53BP1 KMT2A 4864/4885LMNA 3435/4885MEN1 3902/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.